![FDA Watch: Key Lab Test Clearances of 2023](https://www.g2intelligence.com/wp-content/uploads/2024/01/Jan24.LIA_.FDAWatch-iStock-1100x800-1-1080x675.jpg)
FDA Watch: Key Lab Test Clearances of 2023
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
What 2023 Q3 earnings from 30 key US lab companies indicate about the current state of the industry and outlook for 2024.
Labs, patients, and technology must all work together to deliver forward-thinking patient-centered care.
Recent cases involve Medicare’s 14-Day Rule, improper PHI disclosure to a media outlet, kickbacks, and COVID-19 fraud.
Robin Divine, MBA, president and CEO of TriCore Reference Laboratories, discusses key recent developments in the lab industry and predictions for 2024.
Comments on the FDA’s proposed rule to regulate LDTs as in vitro diagnostic devices reveal mixed reactions.
Genialis CEO and co-founder Rafael Rosengarten, PhD, discusses key 2023 AI developments and what they could mean for laboratories.
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.
A brief overview of antimicrobial susceptibility testing, current methods used, and new methods on the horizon.
Polygenic risk scores may offer new screening and risk stratification options for cardiovascular disease—but how valuable are they?